nach oben

Erschienen in:

01.04.2008 | SSIEM Symposium 2007

Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: A review

verfasst von: M. F. B. Silva, C. C. P. Aires, P. B. M. Luis, J. P. N. Ruiter, L. IJlst, M. Duran, R. J. A. Wanders, I. Tavares de Almeida

Erschienen in: Journal of Inherited Metabolic Disease | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Summary

Valproic acid (VPA; 2-n-propylpentanoic acid) is widely used as a major drug in the treatment of epilepsy and in the control of several types of seizures. Being a simple fatty acid, VPA is a substrate for the fatty acid β-oxidation (FAO) pathway, which takes place primarily in mitochondria. The toxicity of valproate has long been considered to be due primarily to its interference with mitochondrial β-oxidation. The metabolism of the drug, its effects on enzymes of FAO and their cofactors such as CoA and/or carnitine will be reviewed. The cumulative consequences of VPA therapy in inborn errors of metabolism (IEMs) and the importance of recognizing an underlying IEM in cases of VPA-induced steatosis and acute liver toxicity are two different concepts that will be emphasized.

Abbott FS, Anari MR (1999) Chemistry and biotransformation. In: Löscher W, ed. Milestones in Drug Therapy-Valproate, Basel: Birkhäuser Verlag, 47–75.

Abbott Laboratories (2007) Clinical Pharmacology of Divalproex, Abbott Laboratories Inc., USA: http://www.rxabbott.com/pdf/depakote.pdf.

Aires CCP, Ruiter JPN, Luis PBM, et al (2007) Studies on the extra-mitochondrial CoA-ester formation of valproic and Δ⁴-valproic acids. Biochim Biophys Acta 1771: 533–543.PubMed

Bailey MJ, Dickinson RG (1996) Chemical and immunochemical comparison of protein adduct formation of four carboxylate drugs in rat liver and plasma. Chem Res Toxicol 9: 659–666.PubMed

Baillie TA (1988) Metabolic activation of valproic acid and drug-mediated hepatotoxicity. Role of the terminal olefin, 2-n-propyl-4-pentenoic acid. Chem Res Toxicol 1: 195–199.PubMed

Baldwin GS, Abbott FS, Nau H (1996) Binding of a valproate metabolite to the trifunctional protein of fatty acid oxidation. FEBS Lett 8: 384, 1: 58–60.

Battino D, Estienne M, Avanzini G (1995) Clinical pharmacokinetics of antiepileptic drugs in paediatric patients Part I: phenobarbital, primidone, valproic acid, ethosuximide and mesuximide. Clin Pharmacokinet 29: 257–286.PubMed

Becker CM, Harris RA (1983) Influence of valproic acid on hepatic carbohydrate and lipid metabolism. Arch Biochem Biophys 223: 381–392.PubMed

Begriche K, Igoudjil A, Pessayre D, Fromenty B (2006) Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 6: 1–28.PubMed

Bjorge SM, Baillie TA (1991) Studies on the β-oxidation of valproic acid in rat liver mitochondrial preparations. Drug Metab Dispos 19: 823–829.PubMed

Bohan TP, Helton E, McDonald I, et al (2001) Effect of l-carnitine treatment for valproate-induced hepatotoxicity. Neurology 56: 1405–1409.PubMed

Booth CL, Pollack GM, Brouwer KLR (1996) Hepatobiliary disposition of valproic acid and valproate glucuronide: use of a pharmacokinetic model to examine the rate-limiting steps and potential sites of drug interactions. Hepatology 23: 771–780.PubMed

Bryant AE, Dreifuss FE (1996) Valproic acid fatalities. III: US experience since 1986. Neurology 46: 465–469.PubMed

Burchell B (1999) Transformation reactions: glucuronidation. In: Woolf TF, ed. Handbook of Drug Metabolism, New York: Marcel Dekker, 153–173.

Burton BS (1882) On the propyl derivatives and decomposition products of ethylacetoacetate. Am Chem J 3: 385–395.

Chabrol B, Mancini J, Chretien D, Rustin P, Munnich A, Pinsard N (1994) Valproate-induced hepatic failure in a case of cytochrome c oxidase deficiency. Eur J Pediatr 153: 133–135.PubMed

Chang TKH, Abbot FS (2006) Oxidative stress as a mechanism of valproic acid-associated hepatotoxicity. Drug Metab Rev 38: 627–639.PubMed

Corkey BE, Hale DE, Glennon MC, et al (1988) Relationship between unusual hepatic acyl Coenzyme A profiles and the pathogenesis of Reye syndrome. J Clin Invest 82: 782–788.PubMed

Cotariu D, Zaidman J (1988) Valproic acid and the liver. Clin Chem 34: 890–897.PubMed

Davis R, Peters DH, McTavish D (1994) Valproic acid-a reappraisal of its pharmacological properties and clinical efficacy in epilepsy. Drugs 47: 332–372.PubMed

De Vivo DC, Bohan TP, Coulter DL, et al (1998) l-Carnitine supplementation in childhood epilepsy: current perspectives. Epilepsia 39: 1216–1225.PubMed

Delarue A, Paut O, Guys JM, et al (2000) Inappropriate liver transplantation in a child with Alpers-Huttenlocher syndrome misdiagnosed as valproate-induced acute liver failure. Pediatr Transplant 4: 67–71.PubMed

DeVane CL (2003) Pharmacokinetics, drug interactions and tolerability of valproic acid. Psychopharmacol Bull 37(Supplement 2): 25–40.PubMed

Dreifuss FE, Langer DH, Moline A, Maxwell E (1989) Valproic acid fatalities. II US experience since 1984. Neurology 39: 201–207.PubMed

Dutta S, Zhang Y, Conway J, et al (2004) Divalproex ER-pharmacokinetics in older children and adolescents. Pediatr Neurol 30: 330–337.PubMed

Evans AM, Fornasini G (2003) Pharmacokinetics of l-carnitine. Clin Pharmacokinet 42: 941–967.PubMed

Farkas V, Bock I, Csako J, Sandor A (1996) Inhibition of carnitine biosynthesis by valproic acid in rats-the biochemical mechanism of inhibition. Biochem Pharmacol 52: 1429–1433.PubMed

Fong JC, Schulz H (1978) On the rate-limiting step of fatty acid oxidation in heart: inhibition of fatty acid oxidation by 4-pentenoic acid. J Biol Chem 253: 6917–6922.PubMed

Fromenty B, Pessayre D (1997) Impaired mitochondrial function in microvesicular steatosis: effects of drugs, ethanol, hormones and cytokines. J Hepatol 26(Supplement 2): 43–53.PubMed

Gerber N, Dickinson RG, Harland RC, et al. (1979) Reye-like syndrome associated with valproic acid therapy. J Pediatr 95: 142–144.PubMed

Gopaul SV, Farrell K, Abbott FS (2000) Identification and characterization of N-acetylcysteine conjugates of valproic acid in humans and animals. Drug Metab Dispos 28: 823–832.PubMed

Granneman GR, Wang S-I, Kesterson JW, Machinist JM (1984) Hepatotoxicity of valproic acid and its metabolites II Intermediary and valproic acid metabolism. Hepatology 4: 1153–1158.PubMed

Gugler R, van Unruh GE (1980) Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet 5: 67–83.PubMed

Hjelm M, Silva LVK, Seakins JWT, Oberholzer VG, Rolles CJ (1986) Evidence of inherited urea cycle defect in a case of fatal valproate toxicity. Br Med J 292: 23–24.

Holt MP and Ju C (2006) Mechanisms of drug-induced liver injury, AAPS J 8: 1, E48–E59.PubMed

Ito M, Ikeda Y, Arnez JG, Finochiaro G, Tanaka K (1990) Theenzymatic basis for the metabolism and inhibitory effects ofvalproic acid: dehydrogenation of valproyl-CoA by 2-methyl-branched-chain acyl-CoA dehydrogenase. BiochimBiophys Acta 1034: 213–218.PubMed

Jakobs C, Löscher W (1978) Identification of metabolites of valproic acid in serum of humans, dog, rat and mouse. Epilepsia 19: 591–602.PubMed

Kassahun K, Farrell K, Abbott FS (1991) Identification and characterization of the glutathione and N-acetylcysteine conjugates of (E)-2-propyl-2,4-pentadienoic acid, a toxic metabolite of valproic acid, in rats and humans. Drug Metab Dispos 19: 525–535.PubMed

Kassahun K, Hu P, Grillo P, Davis MR, Jin L, Baillie TA (1994) Metabolic activation of unsaturated derivatives of valproic acid. Identification of novel glutathione adducts formed through coenzyme A—dependent and -independent processes. Chem-Biol Interact 90: 253–275.PubMed

Katayama H, Watanabe M, Yoshitomi H, et al (1998) Urinary metabolites of valproic acid in epileptic patients. Biol Pharm Bull 21: 304–307.PubMed

Kesterson JW, Granneman GR, Machinist JM (1984) The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies. Hepatology 4: 1143–1152.PubMedCrossRef

Kibayashi M, Nagao M, Chiba S (1999) Influence of valproic acid on the expression of various acyl-CoA dehydrogenases in rats. Pediatr Int 41: 1:52–60.PubMed

König SA, Siemes H, Bläker F, et al (1994) Severe hepatotoxicity during valproate therapy: an update and report of eight new fatalities. Epilepsia 35: 1005–1015.PubMed

König SA, Schenk M, Sick C, et al (1999) Fatal liver failure associated with valproate therapy in a patient with Friedreich’s disease: a review of valproate hepatotoxicity in adults. Epilepsia 40: 1036–1040.PubMed

Kottlors M, Jaksch M, Ketelsen UP, Weiner S, Glocker FX, Lucking CH (2001) Valproic acid triggers acute rhabdomyolysis in a patient with carnitine palmitoyltransferase type II deficiency. Neuromuscul Disord 11: 8, 757–759.PubMed

Krähenbühl S, Brandner S, Kleinle S, Liechti S, Straumann D (2000) Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. Liver 20: 4, 346–348.PubMed

Kuendgen A, Gattermann N (2007) Valproic acid for the treatment of myeloid malignancies. Cancer 110: 943–954.PubMed

Kuhara T, Hirohata Y, Yamada S, Matsumoto I (1978) Metabolism of sodium dipropylacetate in humans. Eur J Drug Metab Pharmacokinet 3: 171–177.

Lam CW, Lou CH, Williams JC, Chan YW, Wong L (1997) Mitochondrial miopathy, encephalopathy, lactic acidosis and stroke like episodes (MELAS) triggered by valproate therapy. Eur J Pediatr 156: 562–564.PubMed

Leão M (1995) Valproate as a cause of hyperammonemia in heterozygotes with ornitine-transcarbamylase deficiency. Neurology 45: 593–595.PubMed

Lee M-H, HongI, Kim M, et al (2007) Gene expression profiles of murine fatty liver induced by the administration of valproic acid, Toxicol Appl Pharmacol 220: 45–59.PubMed

Levy RH, Rettenmeier AW, Anderson GD, et al (1990) Effects of polytherapy with phenytoin, carbamazepine and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clin Pharmacol Ther 48: 225–235.PubMed

Lheureux PER, Penaloza A, Zahir S, Gris M (2005) Science review: carnitine in the treatment of valproic acid-induced toxicity—what is the evidence? Critical Care 9: 431–440.PubMed

Li J, Norwood DL, Mao L-F, Schultz H (1991) Mitochondrial metabolism of valproic acid. Biochemistry 30: 388–394.PubMed

Löscher W (1999) Pharmacological effects and mechanisms of action. In: Löscher W, ed. Milestones in Drug Therapy—Valproate, Basel: Birkhäuser Verlag 7–45.

Löscher W (2002) Basic Pharmacology of valproate: a review ater 35 years of clinical use for the treatment of epilepsy, CNS Drugs, 16: 669–694.PubMed

Löscher W, Böhme G, Schäfer H, Kochen W (1981) Effect of metabolites of valproic acid on the metabolism of GABA in brain and brain nerve endings. Neuropharmacology 20: 1187–1192.PubMed

Matsumoto I, Kuhara T, Yoshino M (1976) Metabolism of branched medium chain length fatty acid II—β-oxidation of sodium dipropylacetate in rats. Biomed Mass Spectrom 3: 235–240.PubMed

Meunier H, Carraz G, Meunier Y, Eymard P, Aimard M (1963) Propriétés pharmacodynamiques de l’acide n-dipropylacétique. 1^er Mémoire: propriétés antiépileptiques. Thérapie 18: 435–438.PubMed

Millington DS, Bohan TP, Roe CR, Yergey AL, Liberato DJ (1985) Valproylcarnitine: a novel drug metabolite identified by fast atom bombardment and thermospray liquid chromatography-mass spectrometry. Clin Chim Acta 145: 69–76.PubMed

Moore KH, Decker BP, Schreefel FP (1988) Hepatic hydrolysis of octanoyl-CoA and valproyl-CoA in control and valproate-treated animals. Int J Biochem 20: 175–178.PubMed

Mortensen PB, Gregersen N, Kølvraa S, Christensen E (1980) The occurrence of C₆–C₁₀ dicarboxylic acids in urine from patients and rats treated with dipropylacetate. Biochem Med 24: 153–161.PubMed

Nau H, Löscher W (1982) Valproic acid: brain and plasma levels of the drug and its metabolites, anticonvulsant effects and γ-aminobutyric acid (GABA) metabolism in the mouse. JPharmacol Exp Ther 220: 654–659.PubMed

Nau H, Rating D, Koch S, Hauser I, Helge H (1981) Valproic acid and its metabolites: placental transfer, neonatal pharmacokinetics, transfer via mother’s milk and clinical status in neonates of epileptic mothers. J Pharmacol Exp Ther 219: 768–777.PubMed

Nau H, Löscher W, Löscher W (1984) Valproic acid and metabolites: pharmacological and toxicological studies. Epilepsia 25: 14–22.

Oechsner M, Steen C, Sturenburg HJ, Kohlschutter A (1998) Hyperammonaemic encephalopathy after initiation of valproate therapy in unrecognised ornithine transcarbamylase deficiency. J Neurol Neurosur Psychiatr 64: 680–682.

Ohashi R, Tamai I, Yabuuchi H, et al (1999) Na⁺-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance. J Pharmacol Exp Ther 291: 778–784.PubMed

Owens MJ, Nemeroff CB (2003) Pharmacology of valproate. Psychopharmacol Bulletin 37(Supplement 2): 17–24.

Papadimitriou A, Servidei S (1991) Late onset lipid storage myopathy due to multiple acyl-CoA dehydrogenase deficiency triggered by valproate. Neuromuscular Disord 1: 247–252.

Perucca E (2002) Pharmacological and therapeutic properties of valproate. CNS Drugs 16: 695–714.PubMed

Pessayre D, Mansouri A, Haouzi D, Fromenty B (1999) Hepatotoxicity due to mitochondrial dysfunction. Cell Biol Toxicol 15: 367–373.PubMed

Ponchault S, van Hoof F, Veitch K (1992) In vitro effects of valproate and valproate metabolites on mitochondrial oxidations: relevance of CoA sequestration to the observed inhibitions. Biochem Pharmacol 43: 11 2435–2442.

Porter RJ, Meldrum BS (2001) Antiseizure drugs. In: Katzung BG, ed. Basic & Clinical Pharmacology. Lange Medical Books/McGraw-Hill, 395–418.

Radatz M, Nau H (1999) Toxicity. In: Löscher W, ed. Milestones in Drug Therapy—Valproate, Basel: Birkhäuser Verlag, 91–128.

Raskind JY, El-Chaar GM (2000) The role of carnitine supplementation during valproic acid therapy. Ann Pharmacother, 34: 630–638.PubMed

Rettenmeier AW, Prickett KS, Gordon WP, et al (1985) Studies on the biotransformation in the perfused rat liver of 2-n-propyl-4-pentenoic acid, a metabolite of the antiepileptic drug valproic acid. Evidence for the formation of chemically reactive intermediates. Drug Metab Dispos 13: 81–96.PubMed

Rettenmeier AW, Gordon WP, Prickett KS, Levy RH, Baillie TA (1986) Biotransformation and pharmacokinetics in the rhesus monkey of 2-n-propyl-4-pentenoic acid, a toxic metabolite of valproic acid. Drug Metab Dispos 14: 454–464.PubMed

Rettenmeier AW, Gordon WP, Barnes H, Baillie TA (1987) Studies on the metabolic fate of valproic acid in the ratusing stable isotope techniques. Xenobiotica 17: 1147–1157.PubMed

Rettie AE, Rettenmeier AW, Howald WN, Baillie TA (1987) Cytochrome P450-catalysed formation of delta 4-VPA, a toxic metabolite of valproic acid. Science 235: 890–893.PubMed

Russell S (2007) Carnitine as an antidote for acute valproate toxicity in children. Curr Opin Pediatr 19: 206–210.PubMed

Sadeque AJM, Fisher MB, Korzekwa KR, Gonzalez FJ, Rettie AE (1997) Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid. J Pharmacol Exp Ther 283: 698–703.PubMed

Scheffner D, König SA, Rauterberg-Ruland I, Kochen W, Hofmann WJ, Unkelbach St (1988) Fatal liver failure in 16 children with valproate therapy. Epilepsia 29: 530–542.PubMed

Schmidt D (1999) Adverse effects and interactions with other drugs. In: Löscher W, ed. Milestones in Drug Therapy—Valproate, Basel: Birkhäuser Verlag, 223–264.

Sewell AC, Bohles HJ, Herwig J, Demirkol M (1995) Neurological deterioration in patients with urea cycle disorders under valproate therapy-a cause for concern. Eur J Pediatr 154: 593–594.PubMed

Shenn DD (1999) Absorption, distribution and excretion. In: Löscher W, ed. Milestones in Drug Therapy—Valproate, Basel: Birkhäuser Verlag 77–90.

Shirley MA, Hu P, Baillie TA (1993) Stereochemical studies on the β-oxidation of valproic acid in isolated rat hepatocytes. Drug Metab Dispos 21: 580–586.PubMed

Shorvon SD (1990) Epidemiology, classification, natural history and genetics of epilepsy. Lancet 336: 93–96.PubMed

Silva MFB, Ruiter JPN, IJlst L, et al (2001a) Synthesis and intramitochondrial levels of valproyl-CoA metabolites. Anal Biochem 290: 60–67.

Silva MFB, Ruiter JPN, IJlst L, et al (2001b) Differential effect of valproate and its Δ²- and Δ⁴-unsaturated metabolites, on the β-oxidation rate of long-chain and medium-chain fatty acids. Chem-Biol Interact 137: 203–212.

Silva MFB, Selhorst J, Overmars H, et al (2001c) Characterization of plasma acylcarnitines in patients under valproate monotherapy using ESI-MS/MS. Clin Biochem 34: 635–638.

Silva MFB, Ruiter JPN, Overmars H, et al (2002) Complete β-oxidation of valproate: cleavage of 3-oxovalproyl-CoA by a mitochondrial 3-oxoacyl-CoA thiolase. Biochem J 362: 755–760.PubMed

Silva MFB, IJlst L, Allers P, et al (2004) Valproyl-dephosphoCoA: a novel metabolite of valproate formed in vitro in rat liver mitochondria. Drug Metab Dispos 32(11): 1304–1310.PubMed

Spahn-Langguth H, Benet LZ (1992) Acylglucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab Rev 24, 5–47.PubMed

Sztajnkrycer MD (2002) Valproic acid toxicity: overview and management. J Toxicol Clin Toxicol 40: 789–801.PubMed

Tein I, Xie ZW (1994) Reversal of valproic acid-associated impairment of carnitine uptake in cultured human skin fibroblasts. Biochem Biophys Res Commun 204: 753–758.PubMed

Thurston JH, Carroll JE, Dodson WE, Hauhart RE, Tash V (1983) Chronic valproate administration reduces fasting ketonemia in children. Neurology 33: 1348–1350.PubMed

Tong V, Teng XW, Chang TKH, Abbot FS (2005) Valproic acid I: time course of lipid peroxidation biomarkers, liver toxicity and valproic acid metabolite levels in rats. Toxicol Sci 86: 427–435.PubMed

Turnbull DM, Bone AJ, Bartlett K, Koundakjian PP, Sherratt HAS (1983) The effects of valproate on intermediary metabolism in isolated rat hepatocytes and intact rats. Biochem Pharmacol 32: 1887–1892.PubMed

Vajda FJ, Donnan GA, Phillips J, Bladin PF (1981) Human brain, plasma and cerebrospinal fluid concentration of sodium valproate after 72 h of therapy. Neurology 31: 486–487.PubMed

Verrotti A, Trotta D, Morgese G, Chiarelli F (2002) Valproate-induced hyperammonemic encephalopathy. Metab Brain Dis 17: 367–373.PubMed

Wagner CA, Lukewille U, Kaltenbach S, et al (2000) Functional and pharmacological characterization of human Na⁺-carnitine cotransporter hOCTN2. Am J Physiol Renal Physiol 279: F584–591.PubMed

Watkins PB, Seeff LB (2006) Drug-induced liver injury: summary of a single topic clinical research conference, Hepatology 43: 3, 618–631.PubMed

Werner T, Treiss I, Kohlmueller D, et al (2007) Effects of valproate on acylcarnitines in children with epilepsy using ESI-MS/MS. Epilepsia 48: 72–76.PubMed

Williams AM, Worrall S, de Jersey J, Dickinson RG (1992) Studies on the reactivity of acylglucuronides – III. Glucuronide-derived adducts of valproic acid and plasma protein and anti-adduct antibodies in humans. Biochem Pharmacol 43: 745–755.PubMed

Wu SP, Shyu MK, Liou HH, Gau CS, Lin CJ (2004) Interaction between anticonvulsants and human placental carnitine transporter. Epilepsia 43: 204–210.

Yao K-W, Mao L-F, Luo MJ, Schulz H (1994) The relationship between mitochondrial activation and toxicity of some substituted carboxylic acids. Chem-Biol Interact 90: 225–234.PubMed

Zaccara G, Messori A, Moroni F (1988) Clinical pharmacokinetics of valproic acid. Clin Pharmacokinet 15: 367–389.PubMed

Zimmerman HJ, Ishak HJ (1982) Valproate-induced hepatic injury: analysis of 23 fatal cases. Hepatology 2: 591–597.PubMedCrossRef

Zschocke J, Ruiter JP, Brand J, et al (2000) Progressive infantile neurodegeneration caused by 2-methyl-3-hydroxybutyryl-CoA dehydrogenase deficiency: a novel inborn error of branched-chain fatty acid and isoleucine metabolism. Pediatr Res 48: 852–855.PubMed

Titel: Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: A review
verfasst von: M. F. B. Silva
C. C. P. Aires
P. B. M. Luis
J. P. N. Ruiter
L. IJlst
M. Duran
R. J. A. Wanders
I. Tavares de Almeida
Publikationsdatum: 01.04.2008
Verlag: Springer Netherlands
Erschienen in: Journal of Inherited Metabolic Disease / Ausgabe 2/2008
Print ISSN: 0141-8955
Elektronische ISSN: 1573-2665
DOI: https://doi.org/10.1007/s10545-008-0841-x

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2008

Pathogenesis of CNS involvement in disorders of amino and organic acid metabolism

Liver cell transplantation for the treatment of inborn errors of metabolism

Apoprotein A-V: An important regulator of triglyceride metabolism

Sanfilippo syndrome: A mini-review

Inherited epithelial transporter disorders—an overview

Hepatic cirrhosis, dystonia, polycythaemia and hypermanganesaemia—A new metabolic disorder